Previous Close | 0.0400 |
Open | 0.0400 |
Bid | 0.0400 x N/A |
Ask | 0.0450 x N/A |
Day's Range | 0.0400 - 0.0400 |
52 Week Range | 0.0400 - 0.1400 |
Volume | |
Avg. Volume | 5,687 |
Market Cap | 2.369M |
Beta (5Y Monthly) | -0.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") is pleased to report the results of the Annual General Meeting of shareholders held on May 18, 2023 (the "AGM"). Each of the director nominees proposed by management for election were elected to the Board of Directors: Sina Pirooz, Mahmoud Aziz, Kevin Bottomley, Jamie Lewin, and Paul Chow. In addition, the ...
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has received approval from the TSX Venture Exchange (the "Exchange") to extend 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months (see July 20, 2022 press release).In addition, Genix would like to provide a correction to the expiry date on 1,218,333 warrants as published July
Vancouver, British Columbia--(Newsfile Corp. - July 20, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months. 2,136,612 warrants which are set to expire on July 24, 2022 will be extended to January 24, 2024. ...